Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunerka, Paweł, Gala, Kamila, Banach, Martyna, Dominowski, Jakub, Hucz-Kalitowska, Joanna, Mulewski, Krzysztof, Hajnal, Agnes, Mikus, Endre G., Smuga, Damian, Zagozda, Marcin, Dubiel, Krzysztof, Pieczykolan, Jerzy, Zygmunt, Beata M., Wieczorek, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377474/
https://www.ncbi.nlm.nih.gov/pubmed/32702053
http://dx.doi.org/10.1371/journal.pone.0236159
_version_ 1783562223924281344
author Gunerka, Paweł
Gala, Kamila
Banach, Martyna
Dominowski, Jakub
Hucz-Kalitowska, Joanna
Mulewski, Krzysztof
Hajnal, Agnes
Mikus, Endre G.
Smuga, Damian
Zagozda, Marcin
Dubiel, Krzysztof
Pieczykolan, Jerzy
Zygmunt, Beata M.
Wieczorek, Maciej
author_facet Gunerka, Paweł
Gala, Kamila
Banach, Martyna
Dominowski, Jakub
Hucz-Kalitowska, Joanna
Mulewski, Krzysztof
Hajnal, Agnes
Mikus, Endre G.
Smuga, Damian
Zagozda, Marcin
Dubiel, Krzysztof
Pieczykolan, Jerzy
Zygmunt, Beata M.
Wieczorek, Maciej
author_sort Gunerka, Paweł
collection PubMed
description Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.
format Online
Article
Text
id pubmed-7377474
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-73774742020-07-27 Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma Gunerka, Paweł Gala, Kamila Banach, Martyna Dominowski, Jakub Hucz-Kalitowska, Joanna Mulewski, Krzysztof Hajnal, Agnes Mikus, Endre G. Smuga, Damian Zagozda, Marcin Dubiel, Krzysztof Pieczykolan, Jerzy Zygmunt, Beata M. Wieczorek, Maciej PLoS One Research Article Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo. Public Library of Science 2020-07-23 /pmc/articles/PMC7377474/ /pubmed/32702053 http://dx.doi.org/10.1371/journal.pone.0236159 Text en © 2020 Gunerka et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gunerka, Paweł
Gala, Kamila
Banach, Martyna
Dominowski, Jakub
Hucz-Kalitowska, Joanna
Mulewski, Krzysztof
Hajnal, Agnes
Mikus, Endre G.
Smuga, Damian
Zagozda, Marcin
Dubiel, Krzysztof
Pieczykolan, Jerzy
Zygmunt, Beata M.
Wieczorek, Maciej
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
title Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
title_full Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
title_fullStr Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
title_full_unstemmed Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
title_short Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
title_sort preclinical characterization of cpl302-253, a selective inhibitor of pi3kδ, as the candidate for the inhalatory treatment and prevention of asthma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377474/
https://www.ncbi.nlm.nih.gov/pubmed/32702053
http://dx.doi.org/10.1371/journal.pone.0236159
work_keys_str_mv AT gunerkapaweł preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT galakamila preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT banachmartyna preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT dominowskijakub preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT huczkalitowskajoanna preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT mulewskikrzysztof preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT hajnalagnes preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT mikusendreg preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT smugadamian preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT zagozdamarcin preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT dubielkrzysztof preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT pieczykolanjerzy preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT zygmuntbeatam preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma
AT wieczorekmaciej preclinicalcharacterizationofcpl302253aselectiveinhibitorofpi3kdasthecandidatefortheinhalatorytreatmentandpreventionofasthma

Ejemplares similares